Suppliers and packagers for generic pharmaceutical drug: cabazitaxel

cabazitaxel

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sanofi Aventis Us	JEVTANA KIT	cabazitaxel	SOLUTION;INTRAVENOUS	201023	NDA	Sanofi-Aventis U.S. LLC	0024-5824-11	1 KIT in 1 CARTON (0024-5824-11) * 5.7 mL in 1 VIAL, GLASS (0024-5823-15) * 5.7 mL in 1 VIAL, GLASS (0024-5822-01)	2010-06-17

Suppliers and packagers for generic pharmaceutical drug: cabazitaxel

Last updated: May 26, 2026

Cabazitaxel suppliers and contract manufacturers: who makes cabazitaxel API and finished-dose products for global markets?

Cabazitaxel supply is concentrated around a small set of active pharmaceutical ingredient (API) producers and a broader pool of contract manufacturers that package cabazitaxel capsules or prepare parenteral presentations for branded and generic-led supply chains. Key practical differentiators for selecting a supplier are: (1) whether the site holds validated sterile manufacturing capabilities for injectable formats, (2) whether it can supply cabazitaxel API under GMP with traceable impurity profiles for regulatory filings, and (3) whether it can support packaging and distribution schedules aligned to oncology procurement cycles.

What companies supply cabazitaxel API and who are the key contract manufacturing players?

Cabazitaxel is typically sourced as small-molecule API from specialty chemical and pharma-intermediate manufacturers, then processed into final dosage forms (oral capsules or parenteral presentations depending on market and brand) by contract manufacturing organizations (CMOs) with oncology-grade quality systems.

API supply chain patterns for cabazitaxel

Common procurement models in cabazitaxel manufacturing ecosystems:

• Dedicated API producers (GMP small-molecule manufacturing with controlled impurity specifications).
• Intermediate makers that feed contracted API routes to a downstream API GMP site.
• CMOs that handle drug-product manufacturing, packaging, and labeling under branded specifications.

What to look for in a cabazitaxel supplier qualification package

To qualify a cabazitaxel vendor for R&D scale or commercial manufacturing, procurement and quality teams typically require:

• GMP certificate for the exact dosage form and manufacturing steps (API or sterile drug product).
• Batch release data showing control of key impurity bands aligned to the applicant’s specification.
• Validation packages for dissolution/disintegration where applicable (oral) or sterility/aseptic controls (injectables).
• Controlled change management history for the specific route and polymorph/crystal form controls if applicable.
• Supply continuity indicators (capacity for API and finished product, lead times, and last change dates).

Which sites are most active in cabazitaxel manufacturing and distribution?

Cabazitaxel supply activity is dominated by the branded originator’s long-established manufacturing network and a second tier of specialty manufacturers that supply either (a) API to generics under commercial supply agreements or (b) finished product to distributors and tenders in regulated markets.

Practical supplier selection by capability

• API-focused suppliers: best for generic API procurement, scale-up for formulation work, and internal drug substance manufacturing.
• Drug-product CMOs: best when packaging and final release testing are required for a finished dossier.
• Cold-chain and sterile-capable suppliers: required where the marketed presentation needs stringent aseptic handling.

How does cabazitaxel supplier availability vary by region (US, EU, APAC)?

Supplier availability tends to track regulatory inspection cadence and the localization of manufacturing for tenders.

• US: procurement is often filtered through FDA-inspection-ready supply networks, with distribution tied to US-specific labeling and batch release documentation.
• EU: EMA-aligned GMP expectations and batch release strategy drive which CMOs can participate for branded supply continuity.
• APAC: a mix of API and drug-product capabilities exists, but qualified partner selection depends on prior inspections and dossier-to-plant linkage.

What dosage forms and presentations drive different cabazitaxel supplier requirements?

Supplier capability requirements change by presentation:

• Injectable/sterile presentations: need aseptic processing, sterility assurance, and robust container-closure integrity controls.
• Oral capsule presentations: require containment for cytotoxic drug handling, capsule filling controls, and dissolution testing.

Even for the same API, drug-product sites may differ materially in:

• packaging format and labeling readiness,
• stability study design and retest period assignment,
• batch release analytics and method validation approach.

What are the highest-risk supplier failure points in cabazitaxel supply?

Common supply continuity risks for cytotoxic oncology drugs like cabazitaxel:

• API site disruptions due to catalyst/intermediate supply constraints on the specific route.
• Impurity drift caused by upstream process changes without full comparability testing.
• Sterile or cytotoxic containment failures at CMOs handling final drug product.
• Labeling/packaging supply chain interruptions in batch release windows.

How do cabazitaxel supply contracts usually structure pricing and volume commitments?

Cabazitaxel supply contracting in oncology procurement commonly uses:

• Annual or multi-year supply agreements with forecast-based call-offs.
• Step-down pricing tied to volume tiers.
• Lead-time and service-level commitments for API release, drug product release, and distribution.

Procurement tends to require:

• explicit allocation rules during shortages,
• quality agreement terms aligned to GMP change notification,
• audit rights and deviation handling SLAs.

How can you screen cabazitaxel suppliers for regulatory readiness quickly?

For fast qualification, teams typically run a structured due-diligence screening:

1. GMP status verification aligned to API vs drug product.
2. Inspection history review for cytotoxic handling and data integrity controls.
3. Method competency check for impurities and assay.
4. Stability program alignment to intended shelf life and storage conditions.
5. Change control and comparability capability evidence.

What patent and exclusivity dynamics affect cabazitaxel supply diversification?

Where cabazitaxel is protected by formulation, method-of-use, or composition-of-matter patents and where regulatory exclusivity applies to specific presentations, new suppliers may be limited by:

• approved generic entry timelines,
• authorized manufacturing arrangements,
• branded tender contracts that keep supply locked in.

Patent constraints shape who can legally market which cabazitaxel presentation, while manufacturing constraints shape who can actually produce at scale.

Key Takeaways

• Cabazitaxel supply splits between GMP API producers and CMOs that execute final drug-product manufacturing and packaging.
• Supplier qualification must be capability-specific: API impurity control for substance buyers and sterile/aseptic oncology controls for drug-product buyers.
• Regional availability and inspection readiness govern which vendors can reliably support commercial oncology tender cycles.
• Contracting models usually rely on forecasted call-offs, allocation rules during shortages, and strict quality agreements to manage batch release risk.

FAQs

What documents should be requested from a cabazitaxel API supplier?

Request GMP certificate for the API manufacturing site, impurity specification and batch release data, change control summaries for the manufacturing route, CoA templates used for commercial release, and stability or retest period evidence tied to the proposed grade.

Can a contract manufacturer supply both cabazitaxel API and finished product?

Only if the supplier has validated GMP capabilities for both drug substance and drug product on the same product chain with approved quality agreements and regulatory-aligned testing methods for release.

What capacity constraints most often impact cabazitaxel availability?

Constraints typically arise from upstream intermediate supply, campaign-limited API production capacity, and limited sterile/aseptic drug-product slots for cytotoxic oncology presentations.

How do impurities in cabazitaxel affect supplier qualification?

Impurity drift can trigger batch rejection or delay regulatory comparability. Buyers should verify that supplier impurity profiles and analytical methods align with the target specification and have demonstrated control across batches.

How should cabazitaxel suppliers be audited for cytotoxic handling compliance?

Audit cytotoxic containment engineering, operator training and gowning procedures, cleaning validation, environmental monitoring where applicable, deviation and CAPA systems, and data integrity controls covering batch records.

---

References

No sources were provided in the prompt, and no verifiable supplier list or company-specific manufacturing site data is included above.